| Document Date: 2015-04-22 23:39:46
Open Document File Size: 81,20 KBShare Result on Facebook
City Barcelona / / Company Lundbeck Australia Pty Ltd / AEs / GE / PBAC / / Country United States / Australia / Spain / US / / Currency USD / / Event Natural Disaster / FDA Phase / / Facility Consumer Comments facility / European College of Neuropsychopharmacology / / MedicalCondition schizophrenia / disease / psychiatric illness / therapy Schizophrenia / tremor / ASPIRE US akathisia / pain / Psychotic disorders / acutely exacerbated schizophrenia / illness / acutely symptomatic schizophrenia / Akathisia / / Organization European College of Neuropsychopharmacology / International Congress / European Union / Medicare Australia PBS / / Person Kane Long-acting / Arch Psychiatry / Gopal Efficacy / Kane Aripiprazole / Max Qty / / / Position TGA Clinical Evaluator / nurse / General / Trial ID/ First Author / / Product olanzapine / Harms Injection / haloperidol / ARI tablets / LAI prescriptions / Aripiprazole LAI Aripiprazole tablets / risperidone / Abilify / Aripiprazole tablets / LAI injection / Aripiprazole / / PublishedMedium Commentary / /
SocialTag |
5.2 ARIPIPRAZOLE, 300 mg injection: modified release [1 x 300 mg vial] (&) inert substance diluent [2 x 3 mL syringe], 400 mg injection: modified release [1 x 400 mg vial] (&) inert substance diluent [2 x 3 mL syringe